Zhang Kai, Wang Ya-Wen, Wang Yan-Yan, Song Yu, Zhu Jiang, Si Peng-Chao, Ma Rong
Department of Breast Surgery, Qilu Hospital of Shandong University, 107 West Wenhua Road, Jinan 250012, Shandong, People's Republic of China.
Health Examination Center, Qilu Hospital of Shandong University, 107 West Wenhua Road, Jinan 250012, Shandong, People's Republic of China.
Gene. 2017 Jul 1;619:10-20. doi: 10.1016/j.gene.2017.03.038. Epub 2017 Mar 27.
Accumulating evidence indicates that human circulating microRNAs (miRNAs) could serve as diagnostic and prognostic biomarkers in various cancers. We aimed to explore novel miRNA biomarkers in the blood of breast cancer patients based on miRNA profiling. A miRCURY™ LNA Array was used to identify differentially altered miRNAs in the whole blood of breast cancer patients (n=6) and healthy controls (n=6). Levels of candidate miRNAs were quantified by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) in whole blood specimens of 15 breast cancer patients and 13 age-matched healthy control individuals. The miRWalk database was used to predict miRNA targets and the DAVID tool was used to identify significant enrichment pathways. A total of 171 differentially expressed miRNAs were identified by microarray, including 169 upregulated and 2 downregulated miRNAs in breast cancer. Five upregulated miRNAs (miR-30b-5p, miR-96-5p, miR-182-5p, miR-374b-5p, and miR-942-5p) were confirmed by qRT-PCR. The areas under the receiver operating characteristic curve of miR-30b-5p, miR-96-5p, miR-182-5p, miR-374b-5p, and miR-942-5p were 0.9333, 0.7692, 0.7590, 0.8256, and 0.8128, respectively. Importantly, upregulation of these five miRNAs was observed even in patients with very early-stage breast cancer. A total of 855 genes were predicted to be targeted by the five miRNAs, and the one cut domain family member 2 gene (ONECUT2) was a shared target of the five miRNAs. Analysis of publicly available data revealed that these dysregulated miRNAs and the target genes were associated with the survival of breast cancer patients. Furthermore, the five miRNAs were significantly enriched in numerous cancer-related pathways, including "MicroRNAs in cancer", "Pathways in cancer", "FoxO signaling pathway", "Ras signaling pathway", "Rap1 signaling pathway", "MAPK signaling pathway", and "PI3K-Akt signaling pathway". Our data support the potential of the five identified miRNAs as novel biomarkers for the detection of breast cancer, and indicate that they may be involved in breast cancer development and progression.
越来越多的证据表明,人类循环中的微小RNA(miRNA)可作为多种癌症的诊断和预后生物标志物。我们旨在基于miRNA谱探索乳腺癌患者血液中的新型miRNA生物标志物。使用miRCURY™ LNA芯片来鉴定乳腺癌患者(n = 6)和健康对照者(n = 6)全血中差异改变的miRNA。通过定量逆转录-聚合酶链反应(qRT-PCR)对15例乳腺癌患者和13例年龄匹配的健康对照个体的全血标本中候选miRNA的水平进行定量。使用miRWalk数据库预测miRNA靶标,并使用DAVID工具鉴定显著富集的途径。通过微阵列共鉴定出171种差异表达的miRNA,其中乳腺癌中有169种上调和2种下调的miRNA。通过qRT-PCR证实了5种上调的miRNA(miR-30b-5p、miR-96-5p、miR-182-5p、miR-374b-5p和miR-942-5p)。miR-30b-5p、miR-96-5p、miR-182-5p、miR-374b-5p和miR-942-5p的受试者工作特征曲线下面积分别为0.9333、0.7692、0.7590、0.8256和0.8128。重要的是,即使在极早期乳腺癌患者中也观察到这5种miRNA的上调。共预测有855个基因是这5种miRNA的靶标,其中单切割域家族成员2基因(ONECUT2)是这5种miRNA的共同靶标。对公开可用数据的分析表明,这些失调的miRNA和靶基因与乳腺癌患者的生存相关。此外,这5种miRNA在许多癌症相关途径中显著富集,包括“癌症中的微小RNA”、“癌症途径”、“FoxO信号通路”、“Ras信号通路”、“Rap1信号通路”、“MAPK信号通路”和“PI3K-Akt信号通路”。我们的数据支持所鉴定的这5种miRNA作为检测乳腺癌的新型生物标志物的潜力,并表明它们可能参与乳腺癌的发生和发展。